Mr. Dean Burns reports

OCUMETICS REPORTS SECOND SUCCESSFUL SURGERY DAY

Ocumetics Technology Corp. has successfully completed its second surgical day in Mexico City as part of its clinical study evaluating the Ocumetics accommodating intraocular lens.

All procedures were completed safely and without any reported issues or complications. These results further strengthen confidence in both the safety profile of the Ocumetics lens and the surgical protocol designed to evaluate its performance. Group 1 patient surgeries are now completed.

Dean Burns, president and chief executive officer of Ocumetics, commented: "We are thrilled with the success of our second surgical day. The momentum we are building in this program gives us great excitement as we move forward in our clinical journey."

The company has not yet received all data from the one-month postoperative examinations of group one, day one, patients. An update will be provided when the one-month postoperative results become available.

The company's first-in-human clinical protocol was strategically designed to address three patient groups. The end points for each group are focused on the following key areas of evaluation as shown below.

Primary end points

• Safety -- establishing a clear baseline of patient health and recovery;

• Distance vision correction -- assessing the Ocumetics lens's ability to restore far vision.

Secondary end points

• Product handling and surgical delivery -- ensuring procedural efficiency and reliability;

• Near reading ability -- evaluating the Ocumetics Lens's ability to restore close-range vision.

About Ocumetics Technology Corp.

Ocumetics is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies. Ocumetics is in the preclinical study phase of a game-changing technology for the ophthalmic industry.

We seek Safe Harbor.